A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
Public ClinicalTrials.gov record NCT05556616. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp alfa. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.
Study identification
- NCT ID
- NCT05556616
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- Modakafusp alfa Drug
- Lenalidomide Drug
- Bortezomib Drug
- Carfilzomib Drug
- Daratumumab Drug
- Pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 12, 2023 (Actual)
- Primary completion
- Jun 4, 2024 (Actual)
- Completion
- Jun 4, 2024 (Actual)
- Last update posted
- Jan 29, 2026
2023 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Scripps Health | San Diego | California | 92121 | — |
| The University of Iowa Hospitals & Clinics | Iowa City | Iowa | 52242 | — |
| Cancer Center At Greater Baltimore Medical Center | Baltimore | Maryland | 21153 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89119 | — |
| NYU Langone Hospital - Long Island | Mineola | New York | 11501 | — |
| New York University School of Medicine | New York | New York | 10016 | — |
| Weill Cornell Medicine/New York Presbyterian Hospital | New York | New York | 10021 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York | 10065 | — |
| Novant Health Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Novant Health Cancer Institute - Forsyth Medical Center | Winston-Salem | North Carolina | 27103 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05556616, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05556616 live on ClinicalTrials.gov.